[Clinical probes using tumor necrosis factor in treatment of neoplastic diseases].
Tumor necrosis factor-TNF is a cytokine that is predominantly produced by the activated macrophages. It was shown that TNF has the antineoplastic activity in vitro or in tumor xenografts on the animals in vivo. Clinical trials phase I and II carried out in many centers assessed toxic effects of TNF administration, as well as its pharmacokinetic and therapeutic effect. The following paper is a survey of the results of clinical trials which could be useful for the assessment of TNF role in oncological immunotherapy.
Szczepanik
A
A
Zakładu Immunologii Klinicznej, i Mikrobiologii Polsko-Amerykańskiego, Instytutu Pediatrii Akademii Medycznej, Krakowie.
Tabor
J
J
Siedlar
M
M
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*
D014409:Tumor Necrosis Factor-alpha
Próby kliniczne zastosowania czynnika martwicy nowotworów (tumor necrosis factor alfa-TNF) w leczeniu chorób nowotworowych.